{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:58:51Z","timestamp":1775577531742,"version":"3.50.1"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypertension is a common condition that is often seen in patients with diabetes. Both diseases increase the risk of morbidity and mortality from CV events and kidney disease progression. Factors that influence blood pressure (BP) control in diabetes include the persons\u2019 genetic background for hypertension and kidney disease, level of obesity and insulin resistance, the magnitude of preexisting kidney disease, and lifestyle factors, such as level of sodium and potassium intake, sleep quality and exercise effort all of which can affect levels of sympathetic nerve activity and contribute to increased BP variability. Lifestyle intervention is a key component to the effective management of diabetes and hypertension and can markedly reduce event rates of both heart and kidney outcomes. The approach to pharmacologic treatment of BP in diabetes is crucial since certain classes of agents for both BP and diabetes confer significant benefits to reduce cardiorenal outcomes.<\/jats:p>","DOI":"10.1093\/ajh\/hpaa067","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T11:08:54Z","timestamp":1586948934000},"page":"935-943","source":"Crossref","is-referenced-by-count":9,"title":["How to Manage Hypertension in People With Diabetes"],"prefix":"10.1093","volume":"33","author":[{"given":"Waleed","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, The University of Chicago Medicine , Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George L","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, The University of Chicago Medicine , Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"2022101108163742600_CIT0001","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/HJH.0000000000002021","article-title":"The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?","volume":"37","author":"Egan","year":"2019","journal-title":"J Hypertens"},{"key":"2022101108163742600_CIT0002","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41598-020-60142-y","article-title":"Diabetes and all-cause mortality, a 18-year follow-up study","volume":"10","author":"Salehidoost","year":"2020","journal-title":"Sci Rep"},{"key":"2022101108163742600_CIT0003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.15344\/2456-8007\/2019\/131","article-title":"Cardiovascular risk reduction associated with pharmacological weight loss: a meta-analysis","volume":"4","author":"Kane","year":"2019","journal-title":"Int J Clin Res Trials"},{"key":"2022101108163742600_CIT0004","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.115.306825","article-title":"Epidemiology of obesity and diabetes and their cardiovascular complications","volume":"118","author":"Bhupathiraju","year":"2016","journal-title":"Circ Res"},{"key":"2022101108163742600_CIT0005","doi-asserted-by":"crossref","first-page":"e13571","DOI":"10.2196\/13571","article-title":"The impact of treatment adherence for patients with diabetes and hypertension on cardiovascular disease risk: protocol for a retrospective cohort study, 2008\u20132018","volume":"8","author":"Su","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"2022101108163742600_CIT0006","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.jacc.2020.03.009","article-title":"Decade long temporal trends in U.S. hypertension related cardiovascular mortality","volume":"75","author":"Nambiar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022101108163742600_CIT0007","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2022101108163742600_CIT0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.117.032582","article-title":"Potential US population impact of the 2017 ACC\/AHA high blood pressure guideline","volume":"137","author":"Muntner","year":"2018","journal-title":"Circulation"},{"key":"2022101108163742600_CIT0009","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","article-title":"ACC\/AHA versus ESC\/ESH on hypertension guidelines: JACC guideline comparison","volume":"73","author":"Bakris","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022101108163742600_CIT0010","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association.","year":"2020","journal-title":"Diabetes Care"},{"key":"2022101108163742600_CIT0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature10405","article-title":"Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk","volume":"478","author":"Ehret","year":"2011","journal-title":"Nature"},{"key":"2022101108163742600_CIT0012","first-page":"56","article-title":"Ethnicity and genetics are more important than diabetes mellitus and hypertension in producing cardiovascular events in patients with the metabolic syndrome: emphasis in the Puerto Rico population","volume":"105","author":"Altieri","year":"2013","journal-title":"Bol Asoc Med P R"},{"key":"2022101108163742600_CIT0013","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/9781118387658.ch74","article-title":"Arterial hypertension in diabetes: etiology and treatment.","volume-title":"International Textbook of Diabetes Mellitus","author":"Flynn","year":"2015"},{"key":"2022101108163742600_CIT0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3945\/ajcn.2009.29028","article-title":"Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension","volume":"92","author":"Yatabe","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"2022101108163742600_CIT0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s12098-012-0777-x","article-title":"Hypertension and obesity: epidemiology, mechanisms and clinical approach","volume":"79","author":"Becton","year":"2012","journal-title":"Indian J Pediatr"},{"key":"2022101108163742600_CIT0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0042-105441","article-title":"A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease","volume":"125","author":"Tajabadi-Ebrahimi","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2022101108163742600_CIT0017","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00125-019-4920-3","article-title":"Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study","volume":"62","author":"G\u00e6de","year":"2019","journal-title":"Diabetologia"},{"key":"2022101108163742600_CIT0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"2022101108163742600_CIT0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.HYP.36.1.20","article-title":"Differentiated long-term effects of intentional weight loss on diabetes and hypertension","volume":"36","author":"Sj\u00f6str\u00f6m","year":"2000","journal-title":"Hypertension"},{"key":"2022101108163742600_CIT0020","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMra064486","article-title":"Sodium and potassium in the pathogenesis of hypertension","volume":"356","author":"Adrogu\u00e9","year":"2007","journal-title":"N Engl J Med"},{"key":"2022101108163742600_CIT0021","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjhyper.2004.08.031","article-title":"Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease","volume":"18","author":"Boudville","year":"2005","journal-title":"Am J Hypertens"},{"key":"2022101108163742600_CIT0022","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"2022101108163742600_CIT0023","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2022101108163742600_CIT0024","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"2022101108163742600_CIT0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"2022101108163742600_CIT0026","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2022101108163742600_CIT0027","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/dom.13248","article-title":"Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants","volume":"20","author":"Buckley","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022101108163742600_CIT0028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","article-title":"Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial","volume":"5","author":"Ueki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022101108163742600_CIT0029","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"2022101108163742600_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.007760","article-title":"Initial single-pill blood pressure-lowering therapy: should it be for most people?","volume":"6","author":"Al Dhabyi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022101108163742600_CIT0031","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"2022101108163742600_CIT0032","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/HYPERTENSIONAHA.118.12051","article-title":"Creatinine bump following antihypertensive therapy","volume":"72","author":"Bakris","year":"2018","journal-title":"Hypertension"},{"key":"2022101108163742600_CIT0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2018.07.015","article-title":"Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT","volume":"73","author":"Malhotra","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2022101108163742600_CIT0034","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.119.14659","article-title":"Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: a post hoc analysis of the SPRINT and ACCORD-BP randomized controlled trials","volume":"75","author":"Collard","year":"2020","journal-title":"Hypertension"},{"key":"2022101108163742600_CIT0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD","volume":"62","author":"Taler","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2022101108163742600_CIT0036","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2022101108163742600_CIT0037","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.2337\/dc20-S011","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2022101108163742600_CIT0038","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","year":"2014","journal-title":"Semin Nephrol"},{"key":"2022101108163742600_CIT0039","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2022101108163742600_CIT0040","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1751-7176.2011.00506.x","article-title":"A compendium of antihypertensive therapy","volume":"13","author":"Ferdinand","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022101108163742600_CIT0041","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-323-42973-3.00022-6","article-title":"Diuretics in hypertension.","volume-title":"Hypertension\u2014A Companion to Braunwald\u2019s the HEART","author":"Carter","year":"2018","edition":"3"},{"key":"2022101108163742600_CIT0042","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11892-007-0031-5","article-title":"Antihypertensive agents, insulin sensitivity, and new-onset diabetes","volume":"7","author":"Sarafidis","year":"2007","journal-title":"Curr Diab Rep"},{"key":"2022101108163742600_CIT0043","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"2022101108163742600_CIT0044","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.hjh.0000234121.48272.67","article-title":"Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients","volume":"24","author":"Kaiser","year":"2006","journal-title":"J Hypertens"},{"key":"2022101108163742600_CIT0045","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Arch Intern Med"},{"key":"2022101108163742600_CIT0046","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"2022101108163742600_CIT0047","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCOUTCOMES.111.962522","article-title":"Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study","volume":"5","author":"Barzilay","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022101108163742600_CIT0048","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.2337\/dc06-1373","article-title":"Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome","volume":"29","author":"Bakris","year":"2006","journal-title":"Diabetes Care"},{"key":"2022101108163742600_CIT0049","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/0091270004263046","article-title":"Blood pressure control and nephroprotection in diabetes","volume":"44","author":"Abbott","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2022101108163742600_CIT0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc13-1870","article-title":"Microalbuminuria as a risk predictor in diabetes: the continuing saga","volume":"37","author":"Bakris","year":"2014","journal-title":"Diabetes Care"},{"key":"2022101108163742600_CIT0051","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diabres.2018.10.002","article-title":"Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: a systematic review and meta-analysis of randomised controlled trials","volume":"146","author":"Usman","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2022101108163742600_CIT0052","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2022101108163742600_CIT0053","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfq471","article-title":"Inflammation, kidney function and albuminuria in the Framingham Offspring cohort","volume":"26","author":"Upadhyay","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2022101108163742600_CIT0054","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022101108163742600_CIT0055","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"2022101108163742600_CIT0056","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2022101108163742600_CIT0057","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/ki.2010.292","article-title":"National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events","volume":"78","author":"Bakris","year":"2010","journal-title":"Kidney Int"},{"key":"2022101108163742600_CIT0058","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jash.2010.03.005","article-title":"Treatment of hypertension in patients with diabetes\u2014an update","volume":"4","author":"Bakris","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"2022101108163742600_CIT0059","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"2022101108163742600_CIT0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"2022101108163742600_CIT0061","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.2337\/db12-1512","article-title":"Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes","volume":"62","author":"Weil","year":"2013","journal-title":"Diabetes"},{"key":"2022101108163742600_CIT0062","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"2022101108163742600_CIT0063","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2022101108163742600_CIT0064","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1751-7176.2010.00397.x","article-title":"Combination therapy in hypertension","volume":"13","author":"Gradman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022101108163742600_CIT0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022101108163742600_CIT0066","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"2022101108163742600_CIT0067","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"2022101108163742600_CIT0068","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"2022101108163742600_CIT0069","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2146\/ajhp090656","article-title":"Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis","volume":"68","author":"Morgado","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"2022101108163742600_CIT0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.2018.0642","article-title":"Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC\/AHA recommendations","volume":"319","author":"de Boer","year":"2018","journal-title":"JAMA"},{"key":"2022101108163742600_CIT0071","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"2022101108163742600_CIT0072","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-019-0920-4","article-title":"Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis","volume":"21","author":"Sternlicht","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"2022101108163742600_CIT0073","first-page":"169","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC"},{"key":"2022101108163742600_CIT0074","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol"},{"key":"2022101108163742600_CIT0075","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaa067\/33654257\/hpaa067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/10\/935\/46427054\/hpaa067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/10\/935\/46427054\/hpaa067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T08:18:36Z","timestamp":1665476316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/33\/10\/935\/5822622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaa067","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,4,20]]}}}